This biological function might be attributed to targeting Mcl-1 and DPYD. Because of its low level of expression in HCC cells, miR-302b will be a potential candidate molecular to improve the efficiency of chemotherapy in the treatment of advanced HCC patients after development of better gene delivery systems. This evidence concerns the gene DPYD and hepatocellular carcinoma.